As of June 30, 2026, Theraclion SA carries a market capitalization of 45.39M, placing it among publicly traded companies globally. Its enterprise value stands at 50.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 45.39M |
| Enterprise Value | 50.34M |
Theraclion SA's next confirmed earnings release is scheduled for April 29, 2027.
| Earnings Date | 4/29/2027 |
As of June 30, 2026, Theraclion SA has 73.10M shares outstanding.
| Shares Outstanding | 73.10M |
These figures are as of June 30, 2026.
| PB Ratio | -120.09 |
| P/TBV Ratio | -28.95 |
As of June 30, 2026, Theraclion SA maintains a current ratio of 1.54, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.54 |
| Debt / Equity | -1,308.73 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 36.00 |
As of the close on November 17, 2026, Theraclion SA's stock has declined approximately 9.61% over the past 52 weeks. The 50-day moving average sits at 0.66, while the 200-day moving average is 0.62.
| 52-Week Price Change | -9.61% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 0.62 |
These figures are as of June 30, 2026. Total book value stands at -378,000.00, with working capital of 2.11M providing operational flexibility.
| Total Debt | 4.95M |
| Equity (Book Value) | -378,000.00 |
| Book Value Per Share | -0.01 |
| Working Capital | 2.11M |
Theraclion SA's most recent stock split took place on July 26, 2016.
| Last Split Date | 7/26/2016 |
Already premium?